Press Releases
PANTHERx® Rare Pharmacy Earns 2026 MMIT Patient Choice Award for Patient Satisfaction
April 28, 2026
PITTSBURGH – PANTHERx® Rare, the trusted leader and innovator in patient access and support services for personalized rare disease care, received the 2026 MMIT Patient Choice Award in the Independent Specialty Pharmacy category during a ceremony at Asembia’s...
Read MorePANTHERx® Rare Selected by UCB as the Exclusive Specialty Pharmacy for the Distribution of KYGEVVI™
March 23, 2026
PITTSBURGH – PANTHERx® Rare, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by UCB as the exclusive specialty pharmacy for the distribution of KYGEVVI™ (doxecitine...
Read MorePANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
March 20, 2026
PITTSBURGH – PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), as the exclusive U.S. Pharmacy...
Read MoreAs Rare Disease Drug Approvals Accelerate, PANTHERx® Releases Research on Strengthening Care Coordination
February 25, 2026
Report released for Rare Disease Day shows that while these diseases are rare, the barriers that patients face are unfortunately all too common PITTSBURGH – As the world prepares to mark Rare Disease Day on February 28, the rare disease community faces...
Read MorePANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
January 8, 2026
PITTSBURGH – PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases,...
Read MorePANTHERx® Rare Selected by Otsuka America Pharmaceutical, Inc. to Dispense VOYXACT® (sibeprenlimab-szsi) for the Treatment of Primary Immunoglobulin A Nephropathy
December 18, 2025
PITTSBURGH – PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Otsuka America Pharmaceutical, Inc. (OAPI) as the exclusive specialty pharmacy...
Read MoreNo posts found